Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx
|ClinicalTrials.gov Identifier: NCT00002454|
Recruitment Status : Unknown
Verified January 2002 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : February 27, 2004
Last Update Posted : July 26, 2011
RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells.
PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx.
|Condition or disease||Intervention/treatment||Phase|
|Precancerous Condition||Biological: autologous tumor cell vaccine||Phase 2|
OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the larynx treated with autogenous vaccine derived from each patient's own tumor.
OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks.
PROJECTED ACCRUAL: Not specified
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx|
|Study Start Date :||December 1971|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002454
|United States, New Jersey|
|New Jersey Medical School|
|Newark, New Jersey, United States, 07103-2714|
|Study Chair:||James M. Oleske, MD||Rutgers, The State University of New Jersey|